TY  - GEN
AU  - Jensen,Donald
AU  - Sherman,Kenneth E
AU  - Hézode,Christophe
AU  - Pol,Stanislas
AU  - Zeuzem,Stefan
AU  - de Ledinghen,Victor
AU  - Tran,Albert
AU  - Elkhashab,Magdy
AU  - Younes,Ziad H
AU  - Kugelmas,Marcelo
AU  - Mauss,Stefan
AU  - Everson,Gregory
AU  - Luketic,Velimir
AU  - Vierling,John
AU  - Serfaty,Lawrence
AU  - Brunetto,Maurizia
AU  - Heo,Jeong
AU  - Bernstein,David
AU  - McPhee,Fiona
AU  - Hennicken,Delphine
AU  - Mendez,Patricia
AU  - Hughes,Eric
AU  - Noviello,Stephanie
TI  - Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders
SN  - 1600-0641
PY  - 2016///0331
KW  - Adult
KW  - Aged
KW  - Antiviral Agents
KW  - administration & dosage
KW  - Carbamates
KW  - DNA, Viral
KW  - genetics
KW  - Drug Administration Schedule
KW  - Drug Carriers
KW  - Drug Therapy, Combination
KW  - Female
KW  - Follow-Up Studies
KW  - Genotype
KW  - Hepacivirus
KW  - Hepatitis C, Chronic
KW  - drug therapy
KW  - Humans
KW  - Imidazoles
KW  - Interferon-alpha
KW  - Isoquinolines
KW  - Male
KW  - Middle Aged
KW  - Polyethylene Glycols
KW  - Pyrrolidines
KW  - Recombinant Proteins
KW  - Ribavirin
KW  - Sulfonamides
KW  - Treatment Outcome
KW  - Valine
KW  - analogs & derivatives
KW  - Viral Load
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.jhep.2015.02.018
ER  -